The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
28131713 |
75 |
Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics. |
Merck Research Laboratories |
25087753 |
240 |
Prediction of Thorough QT study results using action potential simulations based on ion channel screens. |
University Of Oxford |
25155913 |
32 |
Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. |
Astrazeneca |
23200256 |
54 |
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor. |
Astrazeneca |
22409629 |
15 |
Discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone as a potent and selective I(Kur) inhibitor. |
Bristol-Myers Squibb |
11356099 |
20 |
Recent developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. |
Abbott Laboratories |
19888755 |
43 |
Selective Kv1.5 blockers: development of (R)-1-(methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a potential treatment for atrial arrhythmia. |
Wyeth Research |